<p>与英国核退役局签署一项为期 15 年的合同，包括续约选项，以获取最多 400 吨再加工铀（RepU），有潜力每年提供数万剂 212Pb。</p>
<p>与英国国家核实验室（UKNNL）合作，扩大从再加工铀中提取 228Th 的规模，以进一步加工成 212Pb 发生器。</p>
<p>与 SpectronRx 达成协议，开发定制的全资 212Pb 发生器，初步数量的 212Pb 已成功生产。</p>
<p>英国剑桥和波士顿 --（商业新闻）--Bicycle Therapeutics plc（纳斯达克：BCYC），一家基于其专有的双环肽（Bicycle®）技术开创新型治疗药物的制药公司，今天宣布已与英国核退役局（NDA）签署一项为期 15 年的合同，包括续约选项，以获取最多 400 吨再加工铀（RepU）。再加工铀不断再生，提供潜在的可持续 212Pb 供应。Bicycle 计划利用本协议提供的再加工铀开发潜在的救命疗法。</p>
<p>此外，Bicycle 宣布与英国国家核实验室（UKNNL）合作，计划从 NDA 获得的再加工铀中提取 228Th。提取的 228Th 将进一步加工成 224Ra，并装载到由 SpectronRx 专门为 Bicycle 开发的定制 212Pb 发生器中。212Pb 是一种放射性同位素，是针对癌细胞的更强效治疗药物之一，称为靶向α疗法（TAT）。</p>
<p>这一系列定制安排旨在支持 Bicycle®放射性结合物（BRC®）组合的潜在发现、开发和商业供应。</p>
<p>“癌症是一种影响全球数百万人的疾病，撕裂了太多家庭。医学科学的突破为更多癌症患者及其亲人带来了希望，而这一独特的合作关系可能会进一步推动这一工作。将核材料转化为尖端癌症治疗听起来像是科幻小说，但多亏了科学家、研究人员和医生的智慧，这可能成为拯救生命的现实。这项工作正是我们决心支持生命科学创新者，使开创性的治疗成为可能的原因，” 国务大臣 Liz Kendall 说。</p>
<p>“这些新合作关系证明了 Bicycle 在推进独特且令人兴奋的无同位素放射药物组合方面的潜力。我们相信，现在我们拥有了从发现到开发再到商业供应所需的资源和基础设施，能够创建全球首个端到端的 212Pb 放射药物生态系统。我们相信 BRC 的潜力以及我们为特定患者需求整合适当同位素的能力是独特的，并创造了显著的价值创造能力，” Bicycle Therapeutics 首席产品和供应链官 Mike Hannay 博士说。“我们非常感谢英国政府对 Bicycle 开发 BRC 的潜力的认可，以及与我们合作开发定制 212Pb 发生器的 SpectronRx。我们期待推进这些动态合作关系，并开发我们的放射药物管道，潜在改善全球癌症患者的生活。”</p>
<p>“我对我们在确立自己作为放射药物研发潜在领导者方面取得的进展感到高兴。今天的公告是在我们与 Eckert &amp; Ziegler 达成协议以供应一系列放射性同位素用于 BRC 产品制造以及成立由一些世界上最受尊敬的放射药物专家组成的研究与创新顾问委员会（RAB）之前公告的基础上进行的，” Bicycle Therapeutics 首席执行官 Kevin Lee 博士说。“随着我们继续推进新兴的 BRC 管道，目前针对新靶点 EphA2 和 MT1-MMP，我们期待在 2026 年上半年展示初步的 EphA2 人类成像数据，并在 2026 年启动我们自己的 Bicycle 研究。”</p>
<p><strong>关于 Bicycle Therapeutics</strong></p>
<p>Bicycle Therapeutics 是一家临床阶段的制药公司，开发一种新型药物类别，称为 Bicycle®分子，针对现有治疗手段服务不足的疾病。Bicycle 分子是完全合成的短肽，采用小分子支架约束形成两个环，以稳定其结构几何形状。这种约束促进了与目标的高亲和力和选择性结合，使 Bicycle 分子成为药物开发的有吸引力候选者。该公司正在评估 zelenectide pevedotin（前称 BT8009），一种针对 Nectin-4 的 Bicycle®药物结合物（BDC®）；BT5528，一种针对 EphA2 的 BDC 分子，这是一个历史上难以药物化的靶点；以及 BT7480，一种针对 Nectin-4 并激活 CD137 的 Bicycle 肿瘤靶向免疫细胞激动剂（Bicycle TICA®），在公司赞助的临床试验中。此外，该公司正在开发 Bicycle®放射性结合物（BRC®）用于放射药物，并通过各种合作伙伴关系探索利用 Bicycle®技术开发肿瘤以外疾病的治疗。</p>
<p>Bicycle Therapeutics 总部位于英国剑桥，许多关键职能和领导团队成员位于马萨诸塞州剑桥。欲了解更多信息，请访问 bicycletherapeutics.com。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿可能包含根据 1995 年《私人证券诉讼改革法》的安全港条款所作的前瞻性声明。这些声明可能通过诸如 “旨在”、“预期”、“相信”、“可能”、“估计”、“期望”、“预测”、“目标”、“打算”、“可能”、“计划”、“潜在”、“寻求”、“将会” 等词语或类似表达来识别，尽管并非所有前瞻性声明都包含这些词语。本新闻稿中的前瞻性声明包括但不限于以下内容：Bicycle 对其与 NDA、UKNNL 和 SpectronRx 的协议和合作所带来的好处的预期；Bicycle 推进差异化和令人兴奋的同位素无关放射药物组合的能力；Bicycle 利用与 NDA 和 SpectronRx 的协议以及与 UKNNL 的合作创建全球首个端到端 212Pb 放射药物生态系统的能力；Bicycle 根据特定患者需求整合适当同位素以支持显著的价值创造能力的能力；新临床试验的启动、Bicycle 临床试验的进展、报告 Bicycle 临床试验的数据以及 EphA2 人类成像数据的时间；用于放射药物的 BRC 分子的开发；以及通过各种合作伙伴关系利用 Bicycle Therapeutics 的技术开发肿瘤以外疾病的疗法。Bicycle Therapeutics 可能无法实际实现这些前瞻性声明中披露的计划、意图或预期，您不应对这些前瞻性声明过度依赖。实际结果或事件可能因各种因素而与这些前瞻性声明中披露的计划、意图和预期有重大差异，包括：研究和开发中固有的不确定性，以及 Bicycle Therapeutics 产品候选者的临床试验和临床开发的启动、进展和完成的风险；Bicycle 可能无法实现其技术或合作伙伴关系的预期利益的风险；Bicycle 可能无法实现其任何临床开发策略的风险；临床试验结果的时间；先前临床试验和临床前研究的结果是否能预测未来临床试验结果的风险；试验可能有不令人满意的结果的风险；因测试或使用 Bicycle 的产品候选者而产生的潜在不良影响；以及其他重要因素，任何因素都可能导致 Bicycle Therapeutics 的实际结果与前瞻性声明中的结果不同，这些因素在 Bicycle Therapeutics 于 2025 年 10 月 30 日向证券交易委员会（SEC）提交的 10-Q 季度报告的 “风险因素” 部分中有更详细的描述，以及 Bicycle Therapeutics 未来可能向 SEC 提交的其他文件。本新闻稿中包含的任何前瞻性声明仅在本日期有效，Bicycle Therapeutics 明确声明不承担更新本声明的任何义务，无论是由于任何新信息、未来事件、情况变化或其他原因，法律另有要求的除外。</p>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMTUwMzc2NTlyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMTUwMzc2NTlyMQ"/></p>
<p>在 businesswire.com 上查看源版本：https://www.businesswire.com/news/home/20251215037659/en/</p>
<p><strong>投资者：</strong> Matthew DeYoung</p>
<p>Argot Partners</p>
<p>ir@bicycletx.com</p>
<p>212-600-1902</p>
<p><strong>媒体：</strong> Deborah Elson</p>
<p>Argot Partners</p>
<p>media@bicycletx.com</p>
<p>来源：Bicycle Therapeutics plc</p>

BCYC

<p>Bicycle Therapeutics 已建立战略合作伙伴关系，以创建其放射药物管道的端到端供应链。这包括与英国核退役局签订的为期 15 年的合同，用于再加工铀，以及与英国国家核实验室和 SpectronRx 的合作，以开发 212Pb 发生器。这些合作伙伴关系旨在推动 Bicycle 的放射药物组合，并支持癌症治疗创新</p>

<p><em>Execution of a 15-year contract including an option to renew with UK Nuclear Decommissioning Authority for access to up to 400 tonnes of reprocessed uranium (RepU), with the potential to deliver tens of thousands of doses of 212Pb every year</em></p>
<div class="lb-trans"><p>与英国核退役局签署一项为期 15 年的合同，包括续约选项，以获取最多 400 吨再加工铀（RepU），有潜力每年提供数万剂 212Pb。</p>
</div><p><em>Partnership with the United Kingdom National Nuclear Laboratory (UKNNL) to scale up the extraction of 228Th from RepU for onward processing into a 212Pb generator</em></p>
<div class="lb-trans"><p>与英国国家核实验室（UKNNL）合作，扩大从再加工铀中提取 228Th 的规模，以进一步加工成 212Pb 发生器。</p>
</div><p><em>Agreement with SpectronRx to develop a bespoke wholly owned 212Pb generator, with initial quantities of 212Pb successfully produced</em></p>
<div class="lb-trans"><p>与 SpectronRx 达成协议，开发定制的全资 212Pb 发生器，初步数量的 212Pb 已成功生产。</p>
</div><p>CAMBRIDGE, England &amp; BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced it has entered into a 15-year contract including an option to renew with the UK Nuclear Decommissioning Authority (NDA) for access to up to 400 tonnes of reprocessed uranium (RepU). RepU continually regenerates providing a potentially sustainable supply of 212Pb. Bicycle intends to utilize the RepU provided by this agreement in its development of potential lifesaving therapies.</p>
<div class="lb-trans"><p>英国剑桥和波士顿 --（商业新闻）--Bicycle Therapeutics plc（纳斯达克：BCYC），一家基于其专有的双环肽（Bicycle®）技术开创新型治疗药物的制药公司，今天宣布已与英国核退役局（NDA）签署一项为期 15 年的合同，包括续约选项，以获取最多 400 吨再加工铀（RepU）。再加工铀不断再生，提供潜在的可持续 212Pb 供应。Bicycle 计划利用本协议提供的再加工铀开发潜在的救命疗法。</p>
</div><p>In addition, Bicycle announced a collaboration with United Kingdom National Nuclear Laboratory (UKNNL), pursuant to which it plans to extract 228Th from the RepU obtained from NDA. The extracted 228Th will then be further processed into 224Ra and loaded into a bespoke 212Pb generator being developed exclusively for Bicycle by SpectronRx. 212Pb is a radioisotope and one of the more potent therapeutic payloads against cancer cells known as Targeted Alpha Therapy (TAT).</p>
<div class="lb-trans"><p>此外，Bicycle 宣布与英国国家核实验室（UKNNL）合作，计划从 NDA 获得的再加工铀中提取 228Th。提取的 228Th 将进一步加工成 224Ra，并装载到由 SpectronRx 专门为 Bicycle 开发的定制 212Pb 发生器中。212Pb 是一种放射性同位素，是针对癌细胞的更强效治疗药物之一，称为靶向α疗法（TAT）。</p>
</div><p>Collectively, this bespoke set of arrangements is designed to support the potential discovery, development, and commercial supply of a portfolio of Bicycle® Radioconjugates (BRC®) containing 212Pb.</p>
<div class="lb-trans"><p>这一系列定制安排旨在支持 Bicycle®放射性结合物（BRC®）组合的潜在发现、开发和商业供应。</p>
</div><p>“Cancer is a disease that affects millions worldwide, and tears too many families apart. Breakthroughs in medical science are giving more cancer patients and their loved ones hope, and this unique partnership could help take that work even further. Turning nuclear material into cutting-edge cancer treatments sounds like science fiction – but thanks to the brilliance of scientists, researchers and doctors, it could be a life-saving reality. Work like this shows exactly why we’re determined to support our life sciences innovators to make groundbreaking new treatments possible,” said Liz Kendall, Secretary of State.</p>
<div class="lb-trans"><p>“癌症是一种影响全球数百万人的疾病，撕裂了太多家庭。医学科学的突破为更多癌症患者及其亲人带来了希望，而这一独特的合作关系可能会进一步推动这一工作。将核材料转化为尖端癌症治疗听起来像是科幻小说，但多亏了科学家、研究人员和医生的智慧，这可能成为拯救生命的现实。这项工作正是我们决心支持生命科学创新者，使开创性的治疗成为可能的原因，” 国务大臣 Liz Kendall 说。</p>
</div><p>“These new collaborations are testaments to the potential of Bicycle to advance a differentiated and exciting isotope agnostic radiopharmaceuticals portfolio. We believe we now have the resources and infrastructure we need to create the world’s first end-to-end 212Pb radiopharmaceutical ecosystem from discovery through development to commercial supply. We believe the potential of BRCs and our ability to incorporate the appropriate isotopes for specific patient needs is unique and creates significant value-creating capabilities,” said Mike Hannay, D.Sc., FRPharmS, chief product and supply chain officer of Bicycle Therapeutics. “We are incredibly grateful to the UK government for their recognition of Bicycle’s potential to develop BRCs with a 15-year access agreement for reprocessed uranium, and to our partners SpectronRx with whom we are developing a bespoke 212Pb generator. We look forward to advancing these dynamic collaborations and developing our pipeline of radiopharmaceuticals with the potential of improving lives for cancer patients around the globe.”</p>
<div class="lb-trans"><p>“这些新合作关系证明了 Bicycle 在推进独特且令人兴奋的无同位素放射药物组合方面的潜力。我们相信，现在我们拥有了从发现到开发再到商业供应所需的资源和基础设施，能够创建全球首个端到端的 212Pb 放射药物生态系统。我们相信 BRC 的潜力以及我们为特定患者需求整合适当同位素的能力是独特的，并创造了显著的价值创造能力，” Bicycle Therapeutics 首席产品和供应链官 Mike Hannay 博士说。“我们非常感谢英国政府对 Bicycle 开发 BRC 的潜力的认可，以及与我们合作开发定制 212Pb 发生器的 SpectronRx。我们期待推进这些动态合作关系，并开发我们的放射药物管道，潜在改善全球癌症患者的生活。”</p>
</div><p>“I am delighted with the progress we are making in establishing ourselves as a potential leader in radiopharmaceutical R&amp;D. Today’s announcement builds on our previous announcements concerning our agreement with Eckert &amp; Ziegler to supply a range of radioisotopes for the manufacture of BRC products as well as the formation of our Research and Innovation Advisory Board (RAB) comprising some of the worlds most esteemed experts in radiopharmaceuticals,” said Bicycle Therapeutics CEO Kevin Lee, Ph.D. “As we continue to advance our emerging BRC pipeline, currently with novel targets EphA2 and MT1-MMP, we look forward to presenting initial EphA2 human imaging data in the first half of 2026 and initiating our own Bicycle study in 2026.”</p>
<div class="lb-trans"><p>“我对我们在确立自己作为放射药物研发潜在领导者方面取得的进展感到高兴。今天的公告是在我们与 Eckert &amp; Ziegler 达成协议以供应一系列放射性同位素用于 BRC 产品制造以及成立由一些世界上最受尊敬的放射药物专家组成的研究与创新顾问委员会（RAB）之前公告的基础上进行的，” Bicycle Therapeutics 首席执行官 Kevin Lee 博士说。“随着我们继续推进新兴的 BRC 管道，目前针对新靶点 EphA2 和 MT1-MMP，我们期待在 2026 年上半年展示初步的 EphA2 人类成像数据，并在 2026 年启动我们自己的 Bicycle 研究。”</p>
</div><p><strong>About Bicycle Therapeutics</strong></p>
<div class="lb-trans"><p><strong>关于 Bicycle Therapeutics</strong></p>
</div><p>Bicycle Therapeutics is a clinical-stage pharmaceutical company developing a novel class of medicines, referred to as Bicycle® molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development. The company is evaluating zelenectide pevedotin (formerly BT8009), a Bicycle® Drug Conjugate (BDC®) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BDC molecule targeting EphA2, a historically undruggable target; and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) targeting Nectin-4 and agonizing CD137, in company-sponsored clinical trials. Additionally, the company is developing Bicycle® Radioconjugates (BRC®) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle® technology to develop therapies for diseases beyond oncology.</p>
<div class="lb-trans"><p>Bicycle Therapeutics 是一家临床阶段的制药公司，开发一种新型药物类别，称为 Bicycle®分子，针对现有治疗手段服务不足的疾病。Bicycle 分子是完全合成的短肽，采用小分子支架约束形成两个环，以稳定其结构几何形状。这种约束促进了与目标的高亲和力和选择性结合，使 Bicycle 分子成为药物开发的有吸引力候选者。该公司正在评估 zelenectide pevedotin（前称 BT8009），一种针对 Nectin-4 的 Bicycle®药物结合物（BDC®）；BT5528，一种针对 EphA2 的 BDC 分子，这是一个历史上难以药物化的靶点；以及 BT7480，一种针对 Nectin-4 并激活 CD137 的 Bicycle 肿瘤靶向免疫细胞激动剂（Bicycle TICA®），在公司赞助的临床试验中。此外，该公司正在开发 Bicycle®放射性结合物（BRC®）用于放射药物，并通过各种合作伙伴关系探索利用 Bicycle®技术开发肿瘤以外疾病的治疗。</p>
</div><p>Bicycle Therapeutics is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Cambridge, Mass. For more information, visit bicycletherapeutics.com.</p>
<div class="lb-trans"><p>Bicycle Therapeutics 总部位于英国剑桥，许多关键职能和领导团队成员位于马萨诸塞州剑桥。欲了解更多信息，请访问 bicycletherapeutics.com。</p>
</div><p><strong>Forward Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: Bicycle’s expectations with respect to the benefits of its agreements and collaborations with NDA, UKNNL, and SpectronRx, respectively; Bicycle’s ability to advance a differentiated and exciting isotope agnostic radiopharmaceuticals portfolio; Bicycle’s ability to leverage its agreements with NDA and SpectronRx and collaboration with UKNNL to create the world’s first end-to-end 212Pb radiopharmaceutical ecosystem; Bicycle’s ability to incorporate the appropriate isotopes for specific patient needs to support significant value-creating capabilities; the initiation of new clinical trials, the progress of Bicycle’s clinical trials, reporting data from Bicycle’s clinical trials and the timing of EphA2 human imaging data; the development of BRC molecules for radiopharmaceutical use; and the use of Bicycle Therapeutics’ technology through various partnerships to develop therapies for diseases beyond oncology. Bicycle Therapeutics may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in research and development and in the initiation, progress and completion of clinical trials and clinical development of Bicycle Therapeutics’ product candidates; the risk that Bicycle may not realize the intended benefits of its technology or partnerships; the risk that Bicycle may not achieve any of its clinical development strategies; timing of results from clinical trials; whether the outcomes of preclinical studies and prior clinical trials will be predictive of future clinical trial results; the risk that trials may have unsatisfactory outcomes; potential adverse effects arising from the testing or use of Bicycle’s product candidates; and other important factors, any of which could cause Bicycle Therapeutics’ actual results to differ from those contained in the forward-looking statements, are described in greater detail in the section entitled “Risk Factors” in Bicycle Therapeutics’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on October 30, 2025, as well as in other filings Bicycle Therapeutics may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and Bicycle Therapeutics expressly disclaims any obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.</p>
<div class="lb-trans"><p>本新闻稿可能包含根据 1995 年《私人证券诉讼改革法》的安全港条款所作的前瞻性声明。这些声明可能通过诸如 “旨在”、“预期”、“相信”、“可能”、“估计”、“期望”、“预测”、“目标”、“打算”、“可能”、“计划”、“潜在”、“寻求”、“将会” 等词语或类似表达来识别，尽管并非所有前瞻性声明都包含这些词语。本新闻稿中的前瞻性声明包括但不限于以下内容：Bicycle 对其与 NDA、UKNNL 和 SpectronRx 的协议和合作所带来的好处的预期；Bicycle 推进差异化和令人兴奋的同位素无关放射药物组合的能力；Bicycle 利用与 NDA 和 SpectronRx 的协议以及与 UKNNL 的合作创建全球首个端到端 212Pb 放射药物生态系统的能力；Bicycle 根据特定患者需求整合适当同位素以支持显著的价值创造能力的能力；新临床试验的启动、Bicycle 临床试验的进展、报告 Bicycle 临床试验的数据以及 EphA2 人类成像数据的时间；用于放射药物的 BRC 分子的开发；以及通过各种合作伙伴关系利用 Bicycle Therapeutics 的技术开发肿瘤以外疾病的疗法。Bicycle Therapeutics 可能无法实际实现这些前瞻性声明中披露的计划、意图或预期，您不应对这些前瞻性声明过度依赖。实际结果或事件可能因各种因素而与这些前瞻性声明中披露的计划、意图和预期有重大差异，包括：研究和开发中固有的不确定性，以及 Bicycle Therapeutics 产品候选者的临床试验和临床开发的启动、进展和完成的风险；Bicycle 可能无法实现其技术或合作伙伴关系的预期利益的风险；Bicycle 可能无法实现其任何临床开发策略的风险；临床试验结果的时间；先前临床试验和临床前研究的结果是否能预测未来临床试验结果的风险；试验可能有不令人满意的结果的风险；因测试或使用 Bicycle 的产品候选者而产生的潜在不良影响；以及其他重要因素，任何因素都可能导致 Bicycle Therapeutics 的实际结果与前瞻性声明中的结果不同，这些因素在 Bicycle Therapeutics 于 2025 年 10 月 30 日向证券交易委员会（SEC）提交的 10-Q 季度报告的 “风险因素” 部分中有更详细的描述，以及 Bicycle Therapeutics 未来可能向 SEC 提交的其他文件。本新闻稿中包含的任何前瞻性声明仅在本日期有效，Bicycle Therapeutics 明确声明不承担更新本声明的任何义务，无论是由于任何新信息、未来事件、情况变化或其他原因，法律另有要求的除外。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMTUwMzc2NTlyMQ" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20251215037659r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20251215037659/en/</p>
<div class="lb-trans"><p>在 businesswire.com 上查看源版本：https://www.businesswire.com/news/home/20251215037659/en/</p>
</div><p><strong>Investors:</strong> Matthew DeYoung</p>
<div class="lb-trans"><p><strong>投资者：</strong> Matthew DeYoung</p>
</div><p>Argot Partners</p>
<div class="lb-trans"><p>Argot Partners</p>
</div><p>ir@bicycletx.com</p>
<div class="lb-trans"><p>ir@bicycletx.com</p>
</div><p>212-600-1902</p>
<div class="lb-trans"><p>212-600-1902</p>
</div><p><strong>Media:</strong> Deborah Elson</p>
<div class="lb-trans"><p><strong>媒体：</strong> Deborah Elson</p>
</div><p>Argot Partners</p>
<div class="lb-trans"><p>Argot Partners</p>
</div><p>media@bicycletx.com</p>
<div class="lb-trans"><p>media@bicycletx.com</p>
</div><p>Source: Bicycle Therapeutics plc</p>
<div class="lb-trans"><p>来源：Bicycle Therapeutics plc</p>
</div>

Bicycle Therapeutics Establishes Multiple Strategic Partnerships to Create End-to-End Supply Chain to Support its Wholly Owned Radiopharmaceutical Pipeline | BCYC Stock News

Bicycle Therapeutics 建立了多个战略合作伙伴关系，以创建端到端供应链，以支持其全资拥有的放射性药物研发管线 | BCYC 股票新闻